Figure 2
Neoadjuvant chemotherapy (NAT) before surgery increase the frequency of BCSC. (a) Frequency of BCSC (Lin-/CD44 + CD24-CD49f + EPCAM+) in healthy donor (HD), breast cancer patients with or without NAT before surgery. (b) Frequency of BCSC in LB patients with or without NAT before surgery. (c) Frequency of BCSC (ALDH +) in HD, breast cancer patients with or without NAT before surgery. (d) Frequency of BCSC (ALDH +) in TN breast cancer patients who received or not NAT before surgery. (AC (Anthracyclines + Ciclophosphamide), AC + TX (Anthracyclines/Ciclophosphamide + Taxanes), TX (Taxanes). Data are presented as violin plots and each point represents an independent sample; dotted lines indicate quartiles. Multiple comparisons were calculated by one-way ANOVA with Tukey post-test analysis and unpaired t-test, significant exact p-value are shown. *p < 0.05; **p < 0.01.
